Spots Global Cancer Trial Database for stage iv laryngeal cancer ajcc v8

Every month we try and update this database with for stage iv laryngeal cancer ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation	NCT05512767	Clinical Stage ... Clinical Stage ... Clinical Stage ... Head and Neck C... Stage II Hypoph... Stage II Laryng... Stage II Lip an... Stage II Oropha... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Best Practice Consensus Audit... Diagnostic Imag... Lymphedema Mana... Modified Barium... Nasopharyngeal ... Pneumatic Compr... Quality-of-Life... Questionnaire A... Voice Handicap ...	18 Years -	Mayo Clinic
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer	NCT06084845	Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Oral Cavity Squ... Oropharyngeal S... Stage III Cutan... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Cutane... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biospecimen Col... Carboplatin Chest Radiograp... Cisplatin Computed Tomogr... Image Guided Ra... Intensity-Modul... Magnetic Resona... Positron Emissi... Xevinapant	18 Years -	Eastern Cooperative Oncology Group
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	NCT05172258	Head and Neck S... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Pembrolizumab	18 Years -	National Cancer Institute (NCI)
A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation	NCT05512767	Clinical Stage ... Clinical Stage ... Clinical Stage ... Head and Neck C... Stage II Hypoph... Stage II Laryng... Stage II Lip an... Stage II Oropha... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Best Practice Consensus Audit... Diagnostic Imag... Lymphedema Mana... Modified Barium... Nasopharyngeal ... Pneumatic Compr... Quality-of-Life... Questionnaire A... Voice Handicap ...	18 Years -	Mayo Clinic
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study	NCT05136196	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Lip and Oral Ca... Melanoma Oropharyngeal S... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study	NCT05136196	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Lip and Oral Ca... Melanoma Oropharyngeal S... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer	NCT03010150	Carcinoma of Un... Clinical Stage ... Clinical Stage ... Clinical Stage ... Metastatic Head... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Stage I Hypopha... Stage I Nasopha... Stage II Hypoph... Stage II Laryng... Stage II Nasoph... Stage II Oropha... Stage III Hypop... Stage III Laryn... Stage III Nasop... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Nasoph... Stage IV Oropha... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Nasop... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Nasop... Stage IVB Oroph...	Biospecimen Col... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT04862650	Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Pathologic Stag... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Squamous Cell C... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Lip a...	Carboplatin Cemiplimab Paclitaxel	18 Years -	Ohio State University Comprehensive Cancer Center
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer	NCT04162873	Clinical Stage ... Clinical Stage ... Nasal Cavity an... Oral Cavity Car... Pathologic Stag... Pathologic Stag... Recurrent Hypop... Recurrent Laryn... Recurrent Nasal... Recurrent Oral ... Recurrent Oroph... Stage III Hypop... Stage III Laryn... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oropha... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oroph...	Celecoxib Placebo Quality-of-Life... Questionnaire A...	18 Years -	University of Utah
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	NCT05172258	Head and Neck S... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Pembrolizumab	18 Years -	National Cancer Institute (NCI)
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT04862650	Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Pathologic Stag... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Squamous Cell C... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Lip a...	Carboplatin Cemiplimab Paclitaxel	18 Years -	Ohio State University Comprehensive Cancer Center
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer	NCT04576091	Clinical Stage ... Clinical Stage ... Recurrent Cutan... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Recurrent Paran... Recurrent Saliv... Stage III Cutan... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Major... Stage III Oroph... Stage III Sinon... Stage IV Cutane... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Major ... Stage IV Oropha... Stage IV Sinona... Unresectable Cu... Unresectable He... Unresectable Hy... Unresectable La... Unresectable Or... Unresectable Or... Unresectable Pa... Unresectable Sa...	Biospecimen Col... Computed Tomogr... Elimusertib Pembrolizumab Positron Emissi... Quality-of-Life... Stereotactic Bo...	18 Years -	National Cancer Institute (NCI)
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers	NCT05063552	Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Lip ... Metastatic Nasa... Metastatic Naso... Metastatic Phar... Metastatic Sino... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Lip a... Recurrent Nasop... Recurrent Phary... Recurrent Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Nasoph... Stage IV Oropha... Stage IV Sinona...	Atezolizumab Bevacizumab Biospecimen Col... Carboplatin Cetuximab Cisplatin Computed Tomogr... Docetaxel Echocardiograph... Magnetic Resona... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment	NCT04788264	Head and Neck C... Hypopharyngeal ... Laryngeal Carci... Maxillary Sinus... Oral Cavity Car... Oropharyngeal C... Paranasal Sinus... Sinonasal Carci... Stage I Larynge... Stage II Laryng... Stage III Laryn... Stage IV Laryng... Stage IVA Laryn... Stage IVB Laryn... Stage IVC Laryn... Lung Carcinoma	Medical Device ... Consultation Exercise Interv... Behavioral Inte... Questionnaire A... Quality of Life...	18 Years -	Thomas Jefferson University
A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation	NCT05512767	Clinical Stage ... Clinical Stage ... Clinical Stage ... Head and Neck C... Stage II Hypoph... Stage II Laryng... Stage II Lip an... Stage II Oropha... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Best Practice Consensus Audit... Diagnostic Imag... Lymphedema Mana... Modified Barium... Nasopharyngeal ... Pneumatic Compr... Quality-of-Life... Questionnaire A... Voice Handicap ...	18 Years -	Mayo Clinic

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: